Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Join us in Lugano, 20-22 March, for 3 days of cutting-edge research, innovative therapies, and collaborative discussions on advancing sarcoma and rare cancers care and outcomes
Enhance your understanding of these significant advancements and have your questions answered. Secure your seat today and be part of this enriching learning experience
The current state of the art in lung cancer therapy
A pioneering forum dedicated to the intersection of AI, digital health and oncology, this new ESMO meeting is not to be missed!
Be the force driving innovation in cancer drug development and make the latest advances in early clinical trials accessible to everyone in Asia
Online application is now open until 27 March 2025
Online application is open until 26 March 2025
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
New data supports the use of artificial intelligence for the administration of immune-check inhibitors in solid tumours
While the field is rapidly evolving, regulatory shifts and greater access to tumour profiling are now needed to realise the full benefits for patients
Early-phase findings report manageable toxicity when combining the PARP inhibitor with the anti-angiogenesis inhibitor in two cohorts of patients with ovarian and castration-resistant prostate tumours
Results from an interim analysis suggest the antibody–drug conjugate alone or in combination with pertuzumab may have a role in the first-line setting
In the TROPION-Lung04 study, no new safety signals were observed with datopotamab deruxtecan plus durvalumab in patients with untreated advanced disease
According to the 2025 ESMO TAT Honorary Awardee, Prof. Philippe Bedard, new technologies have the potential to increase the wealth of information generated from trials and registries
With its new peer-reviewed journal dedicated to rare tumours, ESMO supports knowledge and data sharing among the stakeholders in the field
Final survival data from the TALAPRO-2 study support the use of a PARP inhibitor plus an androgen receptor pathway inhibitor
Recent research suggests a substantial reduction in greenhouse gas emissions with de-escalation per cancer patient
The combination is indicated for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma
The ESMO Sarcoma and Rare Cancers Congress 2025, to be held from 20-22 March in Lugano, Switzerland, will be the convergence point for world-renowned experts to present and discuss developments in the diagnosis and treatment of rare solid tumours, going through their peculiar biology and molecular classification, while also addressing the methodological, organisational, and policy challenges that characterise this oncological area and its high unmet needs
ESMO welcomes the United Nations Secretary-General’s report on non-communicable diseases (NCDs) , which outlines global progress in preventing and controlling cancer and other NCDs, and promoting mental health
Evidence for efficacy is based on the results from the MC-FludT.14/L Trial II
ESMO is committed to improving cancer care and outcomes for patients through its support for Universal Health Coverage (UHC)
Findings from final efficacy and safety analyses from the LIBRETTO-001 study
New data supports the use of artificial intelligence for the administration of immune-check inhibitors in solid tumours
Findings from a retrospective cohort study
This guide is now available in 19 different languages
The combination is indicated for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma
Evidence for efficacy is based on the results from the MC-FludT.14/L Trial II
Findings from final efficacy and safety analyses from the LIBRETTO-001 study
Findings from a retrospective cohort study
Findings from a global cohort of patients harbouring germline pathogenic/likely pathogenic variants in BRCA1 or BRCA2
New indication concerns treatment of adults with limited-stage small cell lung cancer whose disease has not progressed following platinum-based chemoradiation therapy
Evidence for efficacy is based on the results from the DESTINY-Breast06 study
Findings from a systematic review of published studies
Findings from the PEACOCC study
The ESMO Sarcoma and Rare Cancers Congress 2025, to be held from 20-22 March in Lugano, Switzerland, will be the convergence point for world-renowned experts to present and discuss developments in the diagnosis and treatment of rare solid tumours, going through their peculiar biology and molecular classification, while also addressing the methodological, organisational, and policy challenges that characterise this oncological area and its high unmet needs
The ESMO Targeted Anticancer Therapies Congress 2025 will showcase state-of-the-art and the latest advancements in new drug development, with focus on new targets, tumour-agnostic drug development, the role of artificial intelligence in drug development, radiotheranostics and cell therapies for solid tumours
The ESMO Immuno-Oncology Congress 2024 will take place in Geneva, Switzerland, from December 11-13, with an option to attend virtually. Leading experts will present and discuss the research advancements in the rapidly evolving field of immuno-oncology
The ESMO Asia Congress 2024 is the annual event dedicated to multidisciplinary oncology in the Asian region
The Molecular Analysis for Precision Oncology Congress 2024 (MAP) is the appointment where globally recognised experts will present and discuss research in precision medicine, technologies for cancer profiling, mechanisms driving tumour expansion, metastatic dissemination, clonal evolution, and biomarker-driven development of targeted therapeutics
Immunotherapy, which works by enabling the body’s immune system to recognise and destroy cancer cells improves long-term overall survival in patients with advanced melanoma in results from large international studies reported at ESMO 2024
Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, while a first-in-human study found ‘promising’ antitumour activity with a novel antibody drug conjugate (ADC) targeting the protein claudin 6 in heavily pretreated patients with ovarian and endometrial cancers
The ESMO Congress 2024 taking place 13-17 September in Barcelona, Spain, offers a comprehensive view of the current drug development landscape, with existing medicines demonstrating benefit in additional applications and new agents emerging in large numbers as the range of potential molecular targets for therapy continues to expand
The ESMO Congress 2024 will hold a press conference to introduce and discuss the “Eyes to the Future” Presidential Symposium 3, that will be presenting prominent approaches that have the potential to become increasingly effective and influential components of cancer treatment in the (near) future.
The European Society for Medical Oncology (ESMO) announced today that the recipient of the 2025 Heine H. Hansen Award is Keith Kerr, Consultant Pathologist for NHS Grampian and Honorary Chair in Pulmonary Pathology at the University of Aberdeen in Scotland
Burnout is an increasingly pressing concern for the oncology community
This year marks the 10th anniversary of the ESMO Women for Oncology (W4O) Committee, a decade-long commitment to advancing gender equity in oncology
ESMO reaffirms its commitment to working with EU stakeholders to maximize the potential of the Beating Cancer Plan
Bringing together cancer patient advocates from around the world will create a bridge between diverse experiences and perspectives and help secure the optimisation of patient care worldwide
The nomination process for the 2025 ESMO Society Awards is now open
The European Society for Medical Oncology (ESMO) has announced today that the recipient of the 2025 TAT Honorary Award is Philippe Bedard
ESMO welcomes the outcome of the hearings for Olivér Várhelyi, Commissioner-designate for Health and Animal Welfare, where several topics relevant for the oncology community were addressed in a positive or at least promising way
The ESMO Award for Immuno-Oncology 2024 is presented to Ton N. Schumacher in recognition of his exceptional contributions to cancer immunology and to our understanding of the mechanism of how immunotherapy works
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
United Kingdom
Switzerland
France
Switzerland
Peru
Germany
Netherlands
Austria
Spain
Hong Kong SAR, China
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
ESMO Examination 2025 will be held on Saturday 18 October during the ESMO Congress 2025.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
Analytics cookies help us improve our website by collecting and reporting information on its usage.
We use marketing cookies to build a profile of you as a user through your actions on our site in order to better understand your interests and provide you with pertinent suggestions.
